Lifeloc Technologies Q3 net loss narrows as margin improves

By Reuters News


Overview

  • US breathalyzer maker's Q3 net loss narrowed

  • Gross margin improved to 43% from 40% due to price increases, favorable product mix

  • SpinDetect analyzer launch delayed to Q4 2027; high R&D spend contributed to loss


Outlook

  • Lifeloc now expects limited commercial launch of SpinDetect in Q4 2027, delayed from Q1 2027

  • Lifeloc is prioritizing upgrades to core alcohol testing products to boost near-term cash flow


Result Drivers

  • PRICE INCREASES AND PRODUCT MIX - Co said higher prices and a favorable product mix contributed to improved gross margin

  • HIGH R&D SPENDING - Elevated research and development costs, mainly for SpinDetect analyzer, contributed to quarterly loss

  • RESOURCE REALLOCATION - Co is redirecting engineering resources to core products to generate incremental revenue and fund SpinDetect development


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.03

Q3 Net Loss

$85,000

Q3 Gross Margin

43.00%


Reuters Recommended Reads

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall

  • Nov 16 - CNS Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 13 - Tempest Therapeutics Q3 net loss per share narrows on lower R&D expenses


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.